osimertinib
astrazeneca
['osimertinib', 'adaura', 'nsclc', 'sclc', 'aura ,(-laura)']
live at asco 2023, the speak with about his thoughts on the adaura trial presented at asco. the trial assessed osimertinib for egfr-mutated nsclc. keep an eye out for the interview coming soon. #asco2023 
DocWire News delivers the most relevant medical news to over 1M HCPs daily.